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Abstract
Background: In bone tissue engineering (BTE), extensive research into vascular endothelial growth factor A
(VEGFA)-mediated angiogenesis has yielded inconsistent results. The aim of this study was to investigate the influence on
angio- and osteogenesis of adenoviral-mediated delivery of VEGFA alone or in combination with bone morphogenetic
protein 2 (BMP2) in bone marrow stromal cells (BMSC) seeded onto a recently developed poly(LLA-co-CL) scaffold.
Methods: Human BMSC were engineered to express VEGFA alone or in combination with BMP2 and seeded onto
poly(LLA-co-CL) scaffolds. Changes in angiogenic and osteogenic gene and protein levels were examined by
quantitative reverse-transcription polymerase chain reaction (RT-PCR), PCR array, and alkaline phosphatase assay.
An in vivo subcutaneous mouse model was used to investigate the effect on angio- and osteogenesis of VEGFA
alone or in combination with BMP2, using microcomputed tomography (μCT), histology, immunohistochemistry,
and immunofluorescence.
Results: Combined delivery of a lower ratio (1:3) of VEGFA and BMP2 (ad-BMP2 + VEGFA) led to upregulation of
osteogenic and angiogenic genes in vitro at 3 and 14 days, compared with mono-delivery of VEGFA (ad-VEGFA) and
other controls. In vivo, in a subcutaneous mouse model, both ad-VEGFA and ad-BMP2 + VEGFA scaffold explants
exhibited increased angiogenesis at 2 weeks. Enhanced angiogenesis was largely related to the recruitment and
differentiation of mouse progenitor cells to the endothelial lineage and, to a lesser extent, to endothelial differentiation
of the implanted BMSC. μCT and histological analyses revealed enhanced de novo bone formation only in the
ad-BMP2 + VEGFA group, corresponding at the molecular level to the upregulation of genes related to osteogenesis,
such as ALPL, RUNX2, and SPP1.
Conclusions: Although BMSC expressing VEGFA alone or in combination with BMP2 significantly induced
angiogenesis, VEGFA alone failed to demonstrate osteogenic activity both in vitro and in vivo. These results not only
call into question the use of VEGFA alone in bone regeneration, but also highlight the importance in BTE of
appropriately formulated combined delivery of VEGFA and BMP2.
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Background
Bone tissue engineering (BTE) involves an interplay
among mesenchymal stem cells, a supportive scaffold,
and the controlled application of growth factors to pro-
duce vital bone grafts [1]. Selection of appropriate
osteoinductive and/or angiogenic growth factors, a suit-
able delivery method, and a proper supportive scaffold
are critical for a successful outcome in BTE. In addition,
the survival and integration of tissue-engineered con-
structs to the host is critical for the success of BTE and
this is largely dependent on adequate vascularization [2].
Therefore, early induction of vascularization is crucial,
particularly in large bone defects where the vitality of
the implanted cells depends on the vascularity in the
scaffolds. The blood vessels surrounding the scaffold-cell
construct can provide nutrients by diffusion for dis-
tances of 100–200 μm [3]. In this context, various
approaches to improve the vascularization of tissue-
engineered constructs have been explored [4]. The key
events during the early stage of bone repair and regener-
ation (secretion of angiogenic factors, recruitment of
endothelial cells, and stimulation of vascular network
formation) are tightly regulated by a complex interplay
of several growth factors and molecular regulators [5].
An important research challenge is to harness these
crucial events by therapeutic application of angiogenic
molecules, such as vascular endothelial growth factor A
(VEGFA) [6].
There is some evidence that the current mode of
delivery of recombinant growth factors to the defect site
might not be a feasible therapeutic option, given the dis-
advantages of rapid degradation and a short half-life of
the growth factors, unpredictable adverse effects, and
high cost [7, 8]. In vivo delivery of VEGFA protein for a
shorter duration was reported to be less effective in bone
repair, and it has been suggested that sustained release
of VEGFA during the initial angiogenic phase is neces-
sary for optimal healing of the bone defects [9]. A gene
delivery approach is a potential alternative to the protein
delivery method to achieve therapeutic concentration of
single or multiple growth factors [10]. Gene delivery also
allows sustained and regulated delivery of proteins with
authentic post-translational modifications at the defect
site [11].
Multiple growth factors, including VEGFA and the
bone morphogenetic proteins (BMPs; BMP2 to BMP8)
have been shown to enhance bone regeneration in a
number of model systems [9, 12, 13]. The role of
VEGFA in bone repair is attributed to its ability to en-
hance not only angiogenesis but also osteoblastic activity
[9, 14, 15]. The osteoinductive function of BMP2 has
been coupled to its ability to induce VEGFA-mediated
angiogenesis [16, 17]. As both VEGFA and BMP2 are
involved in angiogenesis and osteoinduction and mutually
regulate each other’s biological activity, it has been sug-
gested that combined delivery of these growth factors
might lead to better outcomes for bone regeneration than
mono-delivery of these factors [14, 18].
Accordingly, there are many studies investigating the
influence of combined delivery of VEGFA and BMP2 on
bone regeneration. However, the reported outcomes are
quite inconsistent [16, 19, 20]. For example, using a
critical-sized calvarial bone defect model in the mouse,
Peng et al. demonstrated that combined delivery of a
low ratio (1:5) of VEGFA to BMP2 was more efficient in
bone regeneration than individual delivery of either
BMP2 or VEGFA [16]. Moreover, although at an early
time point (4 weeks) dual delivery resulted in sig-
nificantly enhanced bone formation compared with
individual delivery of either BMP2 or VEGFA, at a later
time point (12 weeks) there was no significant difference
in bone formation between dual delivery and delivery of
BMP2 alone [20]. In contrast, in a rat model, VEGFA was
reported to inhibit BMP2 expression and bone formation
[21]. These inconsistent outcomes clearly support the
need for further studies to optimize the amount and mode
of delivery of VEGFA and BMP2 in bone regeneration.
Another important component of BTE, the scaffold, acts
not only as a carrier for cells and growth factors, but also
functions as a supporting matrix on which cells can differ-
entiate and form mineralized tissue. Ideally, scaffolds
should remain at the defect site, gradually degrading as the
new bone forms [22]. Degradable poly(L-lactide-co-є-
caprolactone) (poly(LLA-co-CL)) scaffold, developed by
our research group, has been extensively evaluated for its
applicability in BTE [23–25]. Using adenoviral-mediated
delivery of BMP2 in human bone marrow stromal cells
(BMSC) seeded onto poly(LLA-co-CL) scaffolds, we have
previously shown that this system is feasible and efficient
in angiogenesis and bone regeneration [13]. In the
current study, using the previously established model,
we aimed to investigate the role of adenoviral-mediated
delivery of VEGFA alone and in combination with BMP2
(VEGFA:BMP2 = 1:3) in angiogenesis and in bone forma-
tion. The results showed that although BMSC expressing
VEGFA alone or in combination with BMP2 significantly
induced angiogenesis, VEGFA alone failed to demonstrate
osteogenic activity both in vitro and in vivo.
Methods
Cell culture
Well-characterized primary human BMSC were purchased
from StemCell Technologies (cat. number: MSC-001 F;
Vancouver, British Columbia, Canada) and expanded using
a MesenCult Proliferation Kit (Stem Cell Technologies,
Part ID 05411) following the standard culture protocol. All
cell culture experiments were carried out in a humidified
atmosphere at 37 °C and 5% CO2. For validation of the
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changes in gene expression induced by adenoviral-
mediated delivery of VEGFA alone or in combination with
BMP2, commercially available human BMSC from two
additional donors were used (henceforth referred to as
donor 2 and 3 BMSC), as described in the supporting
information (Additional file 1).
Preparation of BMSC-seeded scaffolds
Poly(LLA-co-CL) scaffolds were fabricated using the
solvent-casting-salt-leaching method as described previ-
ously [23, 26]. For the in vitro experiments, scaffolds of
diameter ≈ 12 mm, height ≈ 1.3 mm, porosity 85%, and
pore size 90–500 μm, as determined by microcomputed
tomography (μCT), were placed on the bottom of 48-well
plates, pre-wetted with the culture medium, and incu-
bated overnight in a humidified atmosphere at 37 °C and
5% CO2. BMSC were seeded onto the scaffolds at a dens-
ity of 5 × 104 cells/scaffold.
Adenoviral expression vector construction and
transduction of BMSC
Replication-deficient adenoviral expression vectors carrying
the coding sequences of VEGF165 (reference sequence:
NM_001025370.2) (ad-VEGFA) and BMP2 gene (reference
sequence: NM_001200.2) (ad-BMP2) were purchased from
Cyagen Biosciences Inc. In the ad-VEGFA construct, a gene
encoding for DsRed was used as a marker, and in the ad-
BMP2 construct, a gene encoding for enhanced green
fluorescent protein (eGFP) was used. An adenoviral vector
carrying only the eGFP coding sequence (ad-GFP) served as
a control. Adenoviral particles were generated by transfect-
ing HEK 293 cells (ATCC-CRL-1573) with Pac I digested
constructs. Early passage (passages 2–3) BMSC were in-
fected in monolayer culture with respective adenoviruses
(multiplicity of infection (MOI) = 100) to attain 80–90% in-
fection efficiency, confirmed by fluorescent microscopy.
BMSC infected with ad-GFP, ad-VEGFA, and a mixture of
ad-VEGFA and ad-BMP2 (ratio 1:3) are henceforth referred
to as ‘ad-GFP BMSC’, ‘ad-VEGFA BMSC’ and ‘ad-BMP2 +
VEGFA BMSC’, respectively. Based on the results from pre-
vious studies ([14] and references therein), the current study
utilized a lower (1:3) ratio of ad-VEGFA and ad-BMP2 viral
particles (25 MOI of ad-VEGFA and 75 MOI of ad-BMP2)
for the combined BMSC group. After 48 h of infection in
monolayer culture with the respective adenoviral particles,
BMSC were seeded at a density of 5 × 104 cells/scaffold.
BMSC grown in scaffolds were harvested after 3 and 14 days
for mRNA and protein expression analyses. Culture super-
natants were also collected at the respective time points for
enzyme-linked immunosorbent assay (ELISA).
Total RNA extraction
Total RNA from the in vitro seeded scaffolds was
extracted using Maxwell® 16 LEV simplyRNA Kit
(cat no.: AS1270; Promega) on a Maxwell® 16 instrument
in accordance with the manufacturer’s protocol. The
quantity and purity of the total RNA were determined
using a Nanodrop Spectrophotometer (ThermoScientific
Nano Drop Technologies, Wilmington, DE, USA). The
Agilent 2100 Bio analyzer (Agilent Technologies) was
used to examine the integrity of RNA.
Expression analysis of osteogenesis- and
angiogenesis-related genes in vitro using polymerase
chain reaction (PCR) array
To examine the range of genes modulated by the expres-
sion of VEGFA and the co-expression of VEGFA and
BMP2 in BMSC in the three-dimensional scaffold (in
vitro), a custom PCR array (cat no.: 330131; SuperArray
Bioscience, Frederick, MD, USA) containing primer pairs
for 30 genes related to osteogenesis and angiogenesis was
used. Total RNA from three biological replicates (n = 3) of
ad-GFP, ad-VEGFA, and ad-BMP2 +VEGFA groups at 3
and 14 days was used for cDNA synthesis. PCR amplifica-
tion was performed using the following cycling conditions:
95 °C for 10 min, (95 °C for 15 s, and 60 ° C for 1 min) ×
40 cycles in ABI Prism Sequence Detector 7900 HT
(Applied Biosystems, Foster City, USA). Pre- and post-
PCR quality control measures, as recommended by the
manufacturer, were strictly followed. PCR array data were
analyzed as described previously [27]. Briefly, thresh-
old cycle (Ct) was used to calculate the 2–ΔCt value
for each gene using PCR Array Data Analysis Web
Portal (SABiosciences). 2–ΔCt values were then exported to
microarray data analysis software (J-Express 2012). For
statistical analysis, unsupervised hierarchical clustering and
one-way analysis of variance (ANOVA) with Bonferroni
post hoc analysis were used.
Reverse-transcription (RT) and quantitative RT-PCR
(qRT-PCR) using TaqMan assays
Three hundred nanograms of total RNA were con-
verted to cDNA by reverse-transcription reaction using
a high capacity cDNA Archive Kit (Applied Biosystems,
Carlsbad, CA, USA). VEGFA (Hs00900055_m1) and
BMP2 (Hs00154192_m1) TaqMan assays were used to
verify the expression of VEGFA and BMP2 mRNA
levels in adenovirus-transduced BMSC. The in vitro
PCR array results were independently validated by qRT-
PCR, using TaqMan assays for selected key genes: ALPL
(Hs01029144_m1), RUNX2 (Hs00231692_m1), and SPP1
(Hs00959010_m1). GAPDH (Hs99999905_m1) was used
as an endogenous control. All qRT-PCR amplifications
were performed on an ABI Prism Sequence Detector 7900
HT (Applied Biosystems, Foster City, USA) under stand-
ard cycling conditions. A comparative 2–ΔΔCt method was
used to quantify the relative mRNA expression.
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Alkaline phosphatase (ALP) staining
ALP staining was performed to analyze the osteoblastic
differentiation potential of BMSC transduced with re-
spective adenoviral particles. After 48 h of infection the
cells were trypsinized and 2 × 104 cells were seeded in a
monolayer on a four-well culture dish. ALP staining was
performed at 3 and 14 days. Briefly, cells were washed
with phosphate-buffered saline (PBS) and stained for ALP
activity using Napthol AS-TR phosphate and fast red
violet B salt (Sigma-Aldrich) as described previously [28].
BMP2 ELISA
Culture supernatants from the transduced BMSC seeded
onto scaffolds were collected at 3 and 14 days for ELISA
analysis of BMP2 (cat no.: DBP200; R and D systems).
ELISA was performed in duplicates following the manu-
facturer’s instructions.
In vivo subcutaneous implant model in nonobese
diabetic/severe combined immunodeficiency
(NOD/SCID) mice
Preparation of scaffold implants
Poly(LLA-co-CL) scaffolds (diameter ≈ 6 mm, height ≈
1.3 mm) were placed at the bottom of 96-well plates,
pre-wetted with the culture medium, and incubated
overnight in a humidified atmosphere at 37 °C and 5%
CO2. BMSC (5 × 10
5) were seeded onto each scaffold
after 48 h of infection with the respective adenoviral par-
ticles, incubated overnight in a humidified atmosphere
at 37 °C and 5% CO2, and implanted subcutaneously in
NOD/SCID mice. Scaffolds seeded with untransduced
BMSC (untransduced group) and scaffolds without
BMSC (scaffold-only group) were used as additional
controls in the in vivo experiments.
Surgical implantation of scaffolds
All animal experiments were approved by the Norwegian
Animal Research Authority and conducted according to
the European Convention for the Protection of Vertebrates
used for Scientific Purposes (local approval number 4940).
Twenty NOD-SCID mice (6–8 weeks old; Taconic Farms,
Denmark) (10 mice each for the 2- and 8-week time
points) were used for subcutaneous implantation of scaf-
folds. The animals were anesthetized by subcutaneous in-
jection of midazolam 5 mg/ml hyponorm solution. Two
midline surgical incisions approximately 2 cm in length
were made on the backs of the mice and extended laterally
by blunt dissection to create a subcutaneous pouch. Each
animal received four randomly allocated scaffold implants
from the following groups: i) ad-GFP (9 replicates); ii)
ad-VEGFA (9 replicates); iii) ad-VEGF + ad-BMP2 (9 rep-
licates); iv) untransduced (8 replicates); and v) scaffold-
only group (5 replicates), as described previously [13]. The
wounds were closed with Histoacryl Tissue Adhesive
(n-butyl cyanoacrylate) (3 M; St. Paul, MN, USA). At 2
and 8 weeks, the animals were euthanized by CO2 inhal-
ation and subsequent cervical dislocation. The scaffolds re-
trieved at the 2-week time point were cut in half and used
for: i) formalin fixation (fixed in 4% buffered formalin and
decalcified in 12.5% EDTA and 2.5% PFA in PBS) and par-
affin embedding; ii) RNA extraction (stored in RNA later,
Ambion); and iii) cryosection (embedded in Tissue-Tek).
In total, 7 cut halves (replicates) were used for formalin fix-
ation, 6 for RNA extraction, and 5 for cryosection for the
ad-GFP, ad-VEGFA, and ad-BMP2 +VEGFA groups. For
the untransduced group, 6 replicates each were used for
RNA extraction and formalin fixation and 4 for cryosec-
tion. For the scaffold-only group, 3 replicates each were
used for RNA extraction and cryosection, and 4 for forma-
lin fixation. Of the scaffolds retrieved at 8 weeks, 3 ran-
domly selected scaffolds from all the groups were used for
μCT analysis. All remaining scaffolds were formalin fixed
and paraffin embedded (FFPE) for histological analysis.
Expression analysis of osteogenesis- and
angiogenesis-related genes in the in vivo
scaffold explants
For in vivo scaffold explants (2 weeks), 600 ng total
RNA from six biological replicates (n = 6) of ad-GFP, ad-
VEGFA, and ad-BMP2 + VEGFA BMSC groups were
converted to first-strand cDNA using the RT2 First
Strand Kit (C-03; SABiosciences, Frederick, MD, USA).
To examine the range of genes modulated by BMP2
overexpression, a custom PCR array (cat no.: 330131;
SuperArray Bioscience, Frederick, MD, USA) containing
primer pairs for 30 genes related to osteogenesis and
angiogenesis was used. PCR amplification and statistical
analyses were performed as described above for the in
vitro scaffolds.
Histological analysis
The FFPE specimens were cut into 5-μm sections. The
sections were deparaffinized in xylene, rehydrated in
graded ethanol, and stained with hematoxylin and eosin
(H&E). The stained sections were dehydrated, cleared,
and mounted using EuKit mounting medium.
CD31 immunohistochemistry (IHC)
To examine the contribution to angiogenesis in the ex-
plants of cell-autonomous endothelial differentiation of
implanted BMSC, IHC targeting human CD31 protein
was performed on 5-μm thick FFPE tissue specimens of
in vivo scaffold explants harvested at 2 and 8 weeks.
Briefly, antigen retrieval was performed by microwave
treatment in citrate buffer, pH 6.0 (S1699, DAKO). After
blocking with 10% goat serum, monoclonal mouse anti-
human CD31 primary antibody (clone JC70A, DAKO; 1:50
dilution) was applied. After washing, anti-mouse secondary
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antibody conjugated with horseradish peroxidase-labeled
polymer (EnVision System, DAKO) was applied. The
presence of antigen was visualized by staining with
3,3’-diaminobenzidine (DAKO), counterstained with
hematoxylin (DAKO), and mounted with EuKit mounting
medium. Sections incubated with 3% bovine serum albu-
min (BSA) instead of primary antibody served as negative
controls. FFPE tissues from human oral mucosa served as
positive controls. The normal human oral mucosa speci-
men was collected after informed written patient consent
and was approved by the Committee for Medical and
Health Research Ethics in West Norway (ref 2011/1244/
REK vest).
CD31 immunofluorescence (IF)
IF targeting mouse CD31 protein was performed on
8-μm thick frozen tissue specimens of in vivo scaffold ex-
plants harvested at 2 weeks. Briefly, the sections were
fixed in cold acetone (50%, –20 °C) for 10 min, blocked
with 10% goat serum in 3% BSA in PBS and incubated
with rat anti-mouse CD31 (#550274, BD Pharminogen™;
1:250 dilution) for 1 h at room temperature. After washing,
goat anti-rat secondary antibody conjugated with Alexa
Fluor 546 (cat. no.: A-11081; ThermoFisher Scientific,
1:200 dilution) was applied for 30 min in the dark. The
sections were washed and mounted in ProLong® Gold
antifade reagent with DAPI (cat no.: P36935; Invitrogen).
Specimens were examined by confocal laser microscopy
(Leica TCS SP5, Leica Microsystems, Germany). At least
three randomly selected areas, including the periphery and
interior of the explants, were captured from each
specimen. The percentage of CD31-positive areas in the
captured image was calculated using Imaris x64 software
(version 8.4.0).
Western blot analysis
Twenty-five micrograms of protein was resolved in
NuPAGE® Novex 4–10% Bis-Tris gel (Life Technologies,
NY, USA) in NuPAGE® MOPS/MES SDS running buffer
(Life Technologies, NY, USA) and immunoblotted with
monoclonal mouse anti human-VEGF antibody (sc-7269;
Santa Cruz Biotechnology; 1:500 dilution). Anti-GAPDH
antibody (sc-25778; Santa Cruz; 1:5000 dilution) served
as a loading control. The blots were visualized by
enhanced chemiluminescence (Supersignal® West pico;
Pierce Biotechnology, Rockford, IL, USA) and images
were detected in a Fujifilm Las-4000 scanner.
Microcomputed tomography analysis
μCT analysis was carried out by two of the authors (YX
and MAY). Interobserver agreement was high. The in
vivo scaffold explants harvested at 8 weeks were scanned
with a Skyscan 1172 x-ray μCT imaging system (Bruker,
Kontich, Belgium) at 7-μm resolution. The x-ray source
was operated at 50 kV and 200 μA, with a 0.5-mm
aluminum filter. Two-dimensional CT images were
captured every 0.4° through 360° rotation and then re-
constructed by Skyscan NRecon software at thresholds
of 0.0—0.125. Regions of interest were selected, and
three-dimensional analysis was done using Skyscan
Ctan software. Newly formed bone was segmented from
the background using a global threshold of 85–255 and
the morphometric parameter of bone volume (mm3)
was measured by Ctan.
Statistical analyses
Data are expressed as mean ± standard error of the mean
(SEM). ANOVA test with Bonferroni post hoc analysis
was used for comparison of the means of multiple groups.
Statistical analyses were performed using GraphPad Prism
software version 5.00 for Windows (GraphPad Software,
San Diego, CA, USA; www.graphpad.com), with the level
of significance set at 5%.
Results
VEGFA and BMP2 adenoviral expression vectors
upregulated VEGFA and BMP2 mRNA and respective
protein levels
Transduction of BMSC with ad-GFP, ad-VEGFA, and
ad-BMP2 viral particles was efficient (80–90%) and the
transduced cells demonstrated similar morphology in
monoculture (Fig. 1a–e). Compared to the control ad-
GFP BMSC, ad-VEGFA and ad-BMP2 + VEGFA BMSC
seeded onto scaffolds expressed significantly higher
levels of VEGFA mRNA and protein at day 3 and day 14
(Fig. 1f, h). Similarly, significantly higher levels of BMP2
mRNA and secreted BMP2 protein were found in ad-
VEGFA + BMP2 BMSC seeded onto scaffolds at day 3
and 14, compared with the control ad-GFP and ad-
VEGFA BMSC (Fig. 1 g, i).
Adenoviral-mediated combined delivery of VEGFA and
BMP2 was associated with upregulation of osteogenic
and angiogenic markers in vitro
Custom PCR array was used to examine differentially
expressed osteogenesis- and angiogenesis-related genes
with adenoviral-mediated delivery of VEGFA alone or in
combination with BMP2. Unsupervised cluster analysis
showed that replicates of ad-BMP2 + VEGFA BMSC
grown on scaffolds clustered separately from those of
ad-GFP and ad-VEGFA BMSC on both days 3 and 14
(Fig. 2a, b). Correspondingly, the ANOVA test with Bon-
ferroni post hoc analysis showed significant upregulation
of the osteogenic markers ALPL, BMP7, and BMP6 at
day 3, and ALPL, RUNX2, SPP1, BGLAP, BMP6, and
BMP7 at day 14 in ad-BMP2 + VEGFA BMSC compared
with the ad-GFP and ad-VEGFA BMSC (Fig. 2c, d).
Additionally, mRNA expression levels of angiogenesis-
Sharma et al. Stem Cell Research & Therapy  (2018) 9:23 Page 5 of 13
related molecules such as FLT1 (VEGFR1) and its ligand
PGF were significantly upregulated only in ad-BMP2 +
VEGFA BMSC as compared with the ad-GFP and ad-
VEGFA BMSC (Fig. 2c, d). It is of interest to note that
none of the angiogenesis-related markers examined were
significantly overexpressed in ad-VEGFA BMSC. The
mRNA expression level of PECAM1 (encoding CD31 pro-
tein) did not differ significantly among the different
groups at either 3 or 14 days (data not shown). To confirm
the induction of ALPL mRNA at the protein level, ALP
staining was performed. The ALP level was found to be
highly induced at day 3 and persisted at day 14 in ad-
BMP2 + VEGFA BMSC, in contrast to the comparatively
low ALP activity in ad-GFP and ad-VEGFA BMSC (Fig. 2e).
Independent validation of the differentially expressed se-
lected genes, as identified by PCR array, was performed by
qRT-PCR using TaqMan assays for ALPL, RUNX2, and
SPP1. Consistent with the PCR array results, ALPL was
found to be significantly upregulated in ad-BMP2 +
VEGFA BMSC at day 3 (Additional file 2: Figure S1A).
Similarly, at day 14 mRNA levels of ALPL, RUNX2, and
SPP1 were significantly higher in ad-BMP2 +VEGFA
compared with those of ad-GFP and ad-VEGFA BMSC
(Additional file 2: Figure S1B–D). Furthermore, overex-
pression of mRNA levels of ALPL and RUNX2 associated
with the adenoviral-mediated combined delivery of BMP2
Fig. 1 VEGFA and BMP2 adenoviral vectors (ad) respectively upregulated the expression of vascular endothelial growth factor A (VEGFA) and
bone morphogenetic protein 2 (BMP2) in BMSC. Representative immunofluorescence images of BMSC in monolayer transduced with ad-GFP (a),
ad-VEGFA (b), and ad-VEGFA + BMP2 (c–e) adenoviral particles. BMSC (5× 104) were seeded in each scaffold and harvested after 3 and 14 days for
mRNA and protein analyses. Significant upregulation of VEGFA mRNA (f) and VEGFA protein (h) levels were found at both time points in both
ad-VEGFA and ad-BMP2 + ad-VEGFA BMSC compared with the ad-GFP BMSC. Similarly, significant upregulation of BMP2 mRNA (g) was found in
ad-BMP2 + VEGFA BMSC compared with the ad-GFP and ad-VEGFA BMSC at both time points. VEGFA and BMP2 mRNA levels were normalized to
GAPDH mRNA level. i ELISA disclosed higher levels of secreted BMP2 in the culture supernatant of ad-BMP2 BMSC compared with the ad-GFP
BMSC at both 3 and 14 days. Error bars in (f) and (g) represent SEM of three repeated experiments (n = 3) performed in three technical replicates.
ANOVA test with Bonferroni post hoc analysis was used for statistical analysis in (f) and (g) and Student’s t test was performed in (i). Error bars in
(i) represent SEM of three repeated experiments (n = 3). ***p < 0.001, **p < 0.01. GFP green fluorescent protein, ns not significant
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Fig. 2 Adenoviral (ad) vector-mediated combined delivery of bone morphogenetic protein 2 (BMP2) and vascular endothelial growth factor A (VEGFA)
led to upregulation of osteogenic and angiogenic molecules in vitro. ad-GFP, ad-VEGFA, or ad-BMP2 + VEGFA BMSC (5 × 104) were seeded in each
scaffold and harvested at 3 and 14 days for custom polymerase chain reaction (PCR) array and TaqMan-based qRT-PCR. a, b Unsupervised hierarchical
clustering demonstrated two separate clusters consisting of replicates of ad-BMP2 + VEGFA, and replicates of ad-GFP and ad-VEGFA BMSC at both time
points. c ANOVA disclosed that ALPL, BMP7, BMP6, FLT1, and PGF mRNA levels were found to be significantly upregulated at 3 days in ad-BMP2 + VEGFA
BMSC. d More osteogenic markers were significantly induced at 14 days in ad-BMP2 + VEGFA BMSC compared with the ad-GFP and ad-VEGFA BMSC
groups. Error bars represent SEM of three biological replicates (n = 3) performed in three technical replicates. ANOVA test with Bonferroni post hoc
analysis was applied in c and d. e Representative images demonstrating higher alkaline phosphatase activity in ad-BMP2 + VEGFA BMSC in monolayer
culture as compared with the ad-GFP and ad-VEGFA BMSC at 3 and 14 days. Experiments were repeated at least three times. ***p < 0.001, **p < 0.01,
*P < 0.05. GFP green fluorescent protein, ns not significant
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and VEGFA was confirmed in BMSC from two further
donors (donor 2 and donor 3), as described in Additional
file 1 and Additional file 2 (Figure S1E–R).
Adenoviral-mediated delivery of VEGFA alone or in
combination with BMP2 was associated with enhanced
angiogenesis in scaffold explants in NOD/SCID mice
The angiogenic effect of the delivery of VEGFA alone or
in combination with BMP2 in scaffold explants was next
examined using CD31 IF targeting mouse endothelial
cells. Visual inspection disclosed that ad-VEGFA and ad-
BMP2 + VEGFA scaffold explants were more reddish in
color, with the presence of many capillary/vessel-like
structures compared with the control explants at both at
2 and 8 weeks (8-week data not shown) (Fig. 3a). IF
targeting mouse CD31 protein revealed more CD31-
positive areas with multiple capillary-like structures in
ad-VEGFA (40.17 ± 3.17%) and ad-BMP2 + VEGFA
(25.89 ± 2.5%) compared with untransduced (2.98 ± 0.8%)
and ad-GFP (6.14 ± 088%) explants at 2 weeks (Fig. 3b–f ).
To examine the contribution to angiogenesis of cell-
autonomous endothelial differentiation of implanted
BMSC in the explants, IHC targeting human CD31 pro-
tein was performed on FFPE scaffold explants retrieved at
2 and 8 weeks. Except for ad-VEGFA BMSC explants at
8 weeks (Additional file 3: Figure S2E), no CD31 positivity
was observed in the capillary- or vessel-like structures on
the entire scaffold explants for all groups at both 2 and
8 weeks (Additional file 3: Figure S2). Correspondingly,
the level of expression of human PECAM mRNA was
slightly but insignificantly higher in ad-VEGFA explants at
2 weeks (data not shown).
Adenoviral vector-mediated co-expression of VEGFA and
BMP2 induced ectopic bone formation in scaffold
explants in subcutaneous NOD/SCID mice model
The ability of VEGFA alone or in combination with
BMP2 to induce ectopic bone formation in scaffolds was
investigated by subcutaneously implanting unseeded scaf-
folds (scaffold-only), or scaffolds seeded with untrans-
duced or with ad-GFP, ad-VEGFA, and ad-BMP2 +
VEGFA BMSC. μCT analysis revealed barely detectable
radiopaque, bone-like structures in the scaffold-only
explants (data not shown), untransduced (0.0026 ±
0.0014 mm3), ad-GFP (0.0029 ± 0.0023 mm3), or ad-
VEGFA (0.0008 ± 0.0002 mm3) groups at 8 weeks
(Fig. 4a–c, f ). In contrast, all analyzed replicates from ad-
BMP2 + VEGFA explants at 8 weeks revealed the forma-
tion of dense bone-like structure (1.37 ± 0.414 mm3) on
the periphery as well as within the scaffold explant
(Fig. 4d–f ). Histological examination of H&E stained sec-
tions was next performed to confirm the formation of
bone structures in ad-BMP2 +VEGFA explants. As with
the μCT findings, no bony structures were detected in any
replicates of untransduced, ad-GFP, or ad-VEGFA ex-
plants at either 2 or 8 weeks (Fig. 4g–l). However, forma-
tion of bony structures was detected at the periphery of
the scaffold explants in all replicates (7/7) of ad-BMP2 +
VEGFA BMSC at 2 weeks (Fig. 4m). At 8 weeks, formation
of bony structures was more extensive, with bony trabecu-
lae in all the replicates examined (6/6) (Fig. 4n). The bony
structure consisted of numerous osteocyte-like cells at both
2 and 8 weeks. Occasional inflammatory and multinucle-
ated giant cells were detected in all groups (Fig. 4g–n).
Combined delivery of VEGFA- and BMP2-mediated bone
formation is associated with upregulation of osteogenic
and angiogenic molecules in vivo
Custom PCR array was used to examine differentially
expressed osteogenesis- and angiogenesis-related genes
in scaffold explants at 2 weeks. ANOVA showed up-
regulation of osteogenesis-related genes such as ALPL,
RUNX2, and SPP1 in ad-BMP2 + VEGFA explants
compared with the ad-GFP and ad-VEGFA explants
(Fig. 5a–c). Moreover, ANGPT1, an angiogenic factor
which modulates endothelial differentiation, and PGF
were found to be upregulated in ad-BMP2 + VEGFA ex-
plants (Fig. 5d, e). mRNA levels of RUNX2, SPP1,
ANGPT1, and PGF were moderately but nonsignificantly
induced in the ad-VEGFA explants compared with the
ad-GFP explants (Fig. 5b–e).
Comparison of mono-delivery of BMP2 and VEGFA and
combined delivery of BMP2 and VEGFA in angiogenesis
and osteogenesis in vivo
The animal experiments in both the current investigation
and our previous study (using adenoviral-mediated mono-
delivery of BMP2 (ad-BMP2) [13] were carried out at the
same time by the same authors (SS, YX, and DS) and using
the same methodology. This allows comparison of the an-
giogenic and osteogenic effects of mono-delivery of BMP2
[13] with those of the experimental groups in the current
study. The percentage of CD31-positive area (using anti-
mouse CD31) was found to be lower (14.31 ± 2.07%)
in ad-BMP2 compared with ad-VEGFA (40.17 ± 3.17%)
and ad-BMP2 +VEGFA (25.89 ± 2.5%) explants at 2 weeks.
Nevertheless, the amount of bone-like radiopaque
structures was found to be significantly higher in ad-
BMP2 (7.37 ± 0.5834 mm3) than in ad-VEGFA (0.0008 ±
0.0002 mm3) and ad-BMP2 + VEGFA (1.37 ± 0.414 mm3)
explants at 8 weeks.
Discussion
We previously established a model using adenoviral-
mediated delivery of BMP2 to human BMSC seeded onto
recently developed and characterized poly(LLA-co-CL)
scaffolds. We showed that adenoviral-mediated expression
of BMP2 significantly enhanced in vitro osteogenic
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Fig. 3 Adenoviral (ad) vector-mediated expression of vascular endothelial growth factor A (VEGFA) alone and in combination with bone morphogenetic
protein 2 (BMP2) was associated with enhanced angiogenesis in scaffold explants. a Representative images at 2 weeks revealed more reddish scaffold
explants with multiple capillary/vessel like structures (black arrows) radiating from the periphery in ad-VEGFA and ad-BMP2 + VEGFA groups compared
with the other control explants. b–e Frozen sections of scaffold explants at 2 weeks were stained with anti-CD31 targeting mouse CD31 protein and
examined for capillary-like structures. Few CD31-positive structures were found in untransduced and ad-GFP scaffold explants (b and c, white arrows).
However, in ad-VEGFA and ad-BMP2 + VEGFA explants, many CD31-positive capillary-like structures (white arrows) were seen both at the periphery
(not shown in the figure) as well as within the scaffolds (d, e). Red arrowheads indicate remnants of the scaffold material. f Quantification of CD31-positive
area in the scaffold explants at 2 weeks demonstrated significantly more CD31-positive structures in ad-VEGFA and ad-BMP2 + VEGFA (ad-B + V)
scaffolds than in the untransduced and ad-GFP explants. ANOVA test with Bonferroni post hoc analysis was used for statistical analysis in (e). Error bars
represent SEM. ***p < 0.001; **p < 0.01; *P < 0.05. GFP green fluorescent protein, ns not significant
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differentiation and in vivo bone forming ability of BMSC
[13]. Moreover, BMP2 induced pre-angiogenic transcrip-
tional programs in BMSC, both in vitro and in vivo [13].
In the present study, using the above model, we demon-
strated that BMSC expressing VEGFA alone and in com-
bination with BMP2 significantly induced angiogenesis.
However, in contrast to the combined delivery, VEGFA
alone failed to demonstrate osteogenic activity both in
vitro and in vivo in a subcutaneous mouse model.
Although, a wide range of VEGFA/BMP2 ratios have
been tested for their effectiveness in bone regeneration,
it has been proposed that delivery of a lower ratio of
Fig. 4 Combined delivery of bone morphogenetic protein 2 (BMP2) and vascular endothelial growth factor A (VEGFA) induced ectopic bone
formation in scaffold explants in a subcutaneous NOD/SCID mouse model. The ability of VEGFA alone or in combination with BMP2 to induce ectopic
bone formation was investigated in NOD/SCID mice by subcutaneously implanting scaffolds seeded with 5 × 105 BMSC from different experimental
groups. Scaffold explants at 8 weeks were examined by μCT to evaluate ectopic bone formation. Negligible amounts of radiopaque bone-like
structures were detected in a untransduced, b ad-GFP, and c ad-VEGFA BMSC. In contrast, numerous bony-like radiopaque structures were found at
the periphery as well as within the scaffolds of ad-BMP2 + VEGFA explants (d, cross sectional view in e). f Quantification of the radiopaque bone-like
structures in the scaffold explants revealed significant amounts of bone formation in ad-BMP2 + VEGFA scaffolds. g–n Representative images of H&E
stained FFPE sections of scaffold explants from different experimental groups at 2 and 8 weeks. g–l Formation of bony structures was not detected in
untransduced, ad-GFP, or ad-VEGFA groups at either 2 or 8 weeks. m In the ad-BMP2 + VEGFA BMSC group, formation of bony structures (black arrows)
could be seen as early as 2 weeks, mostly at the periphery of the scaffold explants. n Extensive bone formation (green arrows) with bony trabeculae
extending inside the scaffolds was found at 8 weeks in ad-BMP2 + VEGFA BMSC. The structure consisted of numerous osteocyte-like cells at both 2
(black arrowheads, inset in m) and 8 weeks (green arrowheads, inset in n). ANOVA with Bonferroni post hoc analysis was carried out for statistical
analysis in (f). Error bars represent SEM. **p < 0.01. ad adenoviral, GFP green fluorescent protein
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VEGF to BMP2 results in more efficient angiogenic and
osteogenic activity in bone regeneration ([14] and
references therein, [16]). Accordingly, the current study
utilized a ratio of 1:3 of ad-VEGFA to ad-BMP2 to suc-
cessfully express the respective mRNA and proteins in
BMSC (Fig. 1f–i). Transcriptomic analysis using PCR
array, independent validation using TaqMan-based qRT-
PCR, and ALP assay showed upregulation of osteogenic
markers ALPL, RUNX2, BMP7, BMP6, BGLAP, and SPP1
at day 3 or 14 in vitro only in the ad-BMP2 +VEGFA
BMSC compared with the ad-GFP and ad-VEGFA BMSC
(Fig. 2c, d and Additional file 2: Figure S1A–D). These re-
sults suggest that although combined delivery of BMP2 and
VEGFA was able to differentiate the BMSC grown in scaf-
folds towards an osteogenic pathway, VEGFA alone was
not able to do so. Similar gene expression results for osteo-
genic markers were also found only in the ad-BMP2 +
VEGFA BMSC from donors 2 and 3 (Additional file 2:
Figure S1E–R), implying that the osteogenic effects of
combined delivery of BMP2 and VEGFA were not re-
stricted to a certain type of BMSC strain. Additionally,
mRNA expression levels of angiogenesis-related mole-
cules, such as FLT1 (VEGFR1) and its ligand PGF were
significantly upregulated in ad-BMP2 +VEGFA BMSC
compared with the ad-GFP and ad-VEGFA BMSC
(Fig. 3c, d). One possible explanation for the inability of
the ad-VEGFA BMSC group to induce the expression of
FLT1 and PGF could be that, although they are
angiogenesis-related molecules, the FLT1 receptor and its
selective ligand PGF are not the direct downstream tar-
gets of VEGFR2 activation [29]. Moreover, increased
expression of FLT1 and PGF only in ad-BMP2 + VEGFA
BMSC as observed in the current study is very likely
due to BMP2 expression, as shown in our previous
study where adenoviral-mediated expression of BMP2
in BMSC led to higher expression of FLT1 and PGF
mRNA levels [13].
The angiogenic and osteogenic properties of adenoviral-
mediated expression of VEGFA alone and in combination
with BMP2 expression were subsequently investigated by
subcutaneous implantation of scaffolds seeded with BMSC
into NOD/SCID mice. On gross visual examination, scaf-
fold explants from ad-VEGFA and ad-BMP2 + VEGFA
BMSC groups at 2 weeks were more reddish in color, with
many capillary/vessel-like structures radiating out from
the scaffold explants compared with the explants from the
control groups (Fig. 3a), indicating a richer vascular sup-
ply in these scaffold explants. Correspondingly, signifi-
cantly higher numbers of CD31-positive (against mouse
CD31) capillary-like structures were found in ad-VEGFA
and ad-BMP2 +VEGFA explants than in the ad-GFP
explants (Fig. 3b–d). Interestingly, the percentage of
CD31-positive areas was found to be higher in ad-VEGFA
than in the ad-BMP2 +VEGFA (in the current study) or
ad-BMP2 explants [13]. The lower level of angiogenesis in
ad-BMP2 + VEGFA explants is apparently in contrast to
the fact that both VEGFA and BMP2 could induce angio-
genesis. However, the influence of fewer ad-VEGFA virus
particles used in ad-BMP2 +VEGFA (25 MOI, compared
with 100 MOI used in ad-VEGFA group) could not be
completely ruled out. It is noteworthy that very few
capillary-like structures were weakly positive only in ad-
VEGFA BMSC scaffold explants at 8 weeks when incu-
bated with anti-human CD31 antibody (Additional file 3:
Figure S2), suggesting that the induction of capillary for-
mation was mediated largely by the paracrine effect of
VEGFA, leading to the recruitment of mouse endothelial
cells and/or differentiation of mouse progenitor cells to
endothelial lineage in the scaffold explants, rather than by
endothelial differentiation of the implanted BMSC (cell-
autonomous effect). Accordingly, expression of human
PECAM1 was slightly, but insignificantly overexpressed in
ad-VEGFA BMSC explants at 2 weeks (data not shown).
Similar observations were made by Behr et al. using
Fig. 5 Bone morphogenetic protein 2 (BMP2) and vascular endothelial growth factor A (VEGFA) co-expression-mediated bone formation is associated
with upregulation of osteogenic and angiogenic markers in the in vivo scaffold explants. Custom PCR array was used to examine differentially expressed
osteogenesis- and angiogenesis-related genes in scaffold explants at 2 weeks. ANOVA revealed upregulation of a number of osteogenesis- and
angiogenesis-related genes such as a ALPL, b RUNX2, c SPP1 (osteopontin), d ANGPT1, and e PGF in ad-BMP2 + VEGFA explants compared with the ad-GFP
and ad-VEGFA explants. ANOVA test with Bonferroni post hoc analysis was undertaken for statistical analysis. **p < 0.01, **p< 0.05. GFP green fluorescent
protein, ns not significant
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VEGFA-treated human adipose-derived stem cells [30].
Taken together, these findings indicate that both VEGFA
alone or in combination with BMP2 enhances angiogen-
esis in scaffolds seeded with BMSC, primarily by recruit-
ment and differentiation of mouse progenitor cells to the
endothelial lineage and, secondarily, possibly by endothe-
lial differentiation of the implanted BMSC.
After observing increased angiogenesis in ad-VEGFA
and ad-BMP2 + VEGFA explants, the next step was to
explore the osteogenic properties of VEGFA alone and
in combination with BMP2. μCT analysis disclosed
barely detectable radiopaque, bone-like structures in all
the control groups and in the ad-VEGFA explants,
whereas significant amounts were detected in the ad-
BMP2 + VEGFA explants (Fig. 4a–f ). In accordance with
these results, histological examination of H&E stained
sections showed no bony structures in the scaffold
explants from any of the control groups, including ad-
VEGFA BMSC, at either 2 or 8 weeks (Fig. 4g–l). In
contrast, formation of bony structures was observed in
ad-BMP2 + VEGFA scaffold explants as early as 2 weeks,
with further bone formation observed at 8 weeks
(Fig. 4m, n). The presence of numerous osteocyte-like
cells in the bony structures in ad-BMP2 + VEGFA ex-
plants (Fig. 4m, n, insets) suggests that the newly formed
bone in the scaffolds was indeed vital tissue. In corrob-
oration, mRNA expression levels of ALPL, RUNX2, and
SPP1 were significantly upregulated only in ad-BMP2 +
VEGFA explants. That ad-VEGFA BMSC failed to form
bone in the scaffold explants is in accordance with some
previous studies in which expression of VEGFA either
had no osteogenic effect alone, or had no additional
osteogenic effects over BMP2 alone [16, 21, 31]. How-
ever, these observations are inconsistent with some stud-
ies which have shown osteogenic properties of VEGFA
[9, 32]. These differences could be attributable to various
factors, such as the delivery system (controlled release
versus gene therapy), the VEGFA dose, the in vivo model
system used, assessment time points, and the local
microenvironment. Additionally, it is worth mentioning
that ad-BMP2 exhibited the highest degree of bone for-
mation, even though it was associated with the moderate
induction of angiogenesis (least degree of angiogenesis
compared with ad-VEGFA and ad-BMP2 + VEGFA ex-
plants). This indicates that an optimal degree of angio-
genesis might be necessary in bone regeneration. In line
with this suggestion, previous studies have reported that
VEGFA-mediated excessive angiogenesis was associated
with deleterious effects in muscles [33, 34] and embry-
onic myocardium development [35].
Conclusions
Using the previously established model system [13], the
results of this study demonstrate that BMSC expressing
VEGFA alone and in combination with BMP2 signifi-
cantly induced angiogenesis. However, compared with
the combined delivery, VEGFA alone failed to demon-
strate osteogenic activity both in vitro and in vivo in a
subcutaneous mouse model. These findings not only call
into question the use of VEGFA alone for bone regener-
ation, but also highlight the importance of appropriately
formulated combined delivery of VEGFA and BMP2.
Additional files
Additional file 1: Supplementary materials, methods, and results.
(DOCX 13 kb)
Additional file 2: Figure S1. Combined delivery of BMP2 and VEGFA
induced upregulation of ALPL and RUNX2 mRNA levels in ad-BMP2 +
VEGFA BMSC from donors 2 and 3. Independent validation of the
differentially expressed selected genes (ALPL, RUNX2, or SPP1), as identified
by PCR array, was achieved by performing TaqMan-based qRT-PCR for BMSC
from all donors. Compared with the controls, mRNA levels of BMP2, VEGFA,
ALPL, RUNX2, or SPP1 were significantly overexpressed at days 3 or 14 in
ad-BMP2 + VEGFA BMSC from donor 1 (A–D), donor 2 (E–K), and donor
3 (L–R) seeded in scaffolds. Error bars represent SEM of three biological
replicates (n = 3) performed in three technical replicates. ANOVA with
Bonferroni post hoc analysis was performed for statistical analysis.
***p < 0.001; **p < 0.01; *P < 0.05. ns not significant. (TIF 2367 kb)
Additional file 3: Figure S2. A limited number of blood capillaries, only
in ad-VEGFA scaffold explants, were weakly positive for anti-CD31
antibody targeting human CD31 protein. (B–G) No CD31-positive staining
was observed in the capillary/vessel-like structures (black arrows) in the
entire scaffold explants from all groups both at 2 and 8 weeks, except for
a few capillaries in the ad-VEGFA explants at 8 weeks (E, green arrows).
(A) Positive control (normal human oral mucosa) showed multiple
CD31-positive capillary-like structures. (TIF 14626 kb)
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